Skip to content

Award: Boehringer Ingelheim is Global Top Employer 2022

SYDNEY and AUCKLAND, New Zealand
Boehringer Ingelheim is one of the world’s best employers!

-Boehringer Ingelheim advances to one of eleven global top employers worldwide
-This is the second consecutive year for the global certification, and the
second consecutive year for the certification in Australia & New Zealand
-High scores in values, ethics and integrity serve as a driver for a strong
corporate innovation culture

The Top Employers Institute awarded Boehringer Ingelheim for the second year in
succession a “Global Top Employer”, one of the world’s eleven best employers.
The award shows that the research-driven pharmaceutical company is strongly
oriented to the needs and well-being of its employees. Boehringer Ingelheim has
been listed among the top employers in many countries and regions for the past
eight years and this year, Boehringer Ingelheim will receive the award in 29
countries. The independent Top Employers Institute certifies employers
worldwide who wish to offer their employees excellent working conditions and
support their development. Certification is based on a multi-level program to
examine human resources management with detailed final feedback.

In addition to being certified at the global level, Boehringer Ingelheim has
been named as a Top Employer in Australia & New Zealand for the second
consecutive year, as well as across the region in ASEAN and Korea – with over
2,700 employees from 24 different nationalities.

Boehringer Ingelheim continued to thrive in the area of employee engagement
where it particularly stands out with regards to rewards and recognition,
compared to its competitors. The Top Employers Institute also highlighted the
agile work environment as well as the Company’s values, ethics and integrity
that result in the strong, inclusive corporate culture.

“As a family-owned organization that cares for humans and animals, we are
honoured to be recognised by the Top Employers Institute across the region and
globally, once more. We have a strong focus on Sustainable Development for
Generations, where we provide access to health and solutions for societal
challenges. Importantly, we care for our employees who are our greatest assets.
Our people are empowered, respected, and valued – no matter who they are, or
what roles they play,” said Dr Armin Wiesler, Regional Managing Director,
Boehringer Ingelheim (ASEAN, Korea, Australia & New Zealand).

Diversity and Inclusion is driven and demonstrated throughout the organisation.
Tangible behaviours such as encouraging everyone to speak up, being aware of
unconscious bias, treating everyone fairly are not only exhibited by leaders
but employees as well.

“We believe that every employee can contribute with their uniqueness to make
the difference for our customers, patients and partners. Our inclusive culture
also allows for more ideas and innovation to take place. When we put people
first in all that we do and ensure healthy well-being, this too leads to higher
performance for the business,” said David Serés, Human Resources Director,
Boehringer Ingelheim (ASEAN, Korea, Australia & New Zealand).

During the pandemic, the Company’s well-established flexible work arrangements
have empowered employees to actively adapt their work to assist with health
protection requirements, and to ensure business continuity. This also applies
for virtual onboarding processes for which the Company established concepts for
new employees working from home. Another point highlighted by the judges was
the ethical, inclusive approach to corporate decisions and a clear focus on the
transfer and application of company values. The family business also takes care
of individual development opportunities through tailor-made education and
training programs throughout the employee’s working life.

In addition, as part of Boehringer Ingelheim Australia’s long-term commitment
to support Australian communities, for over a decade, the Company has supported
the Smith Family through an annual AUD$50,000 donation to support STEM tertiary
scholarships. Employees also donate their time and skills to volunteer in a
range of Smith Family programs, including mentoring of secondary students. With
a strong culture of volunteering, employees initiated around 20 fundraising
activities across Australia for local community causes which they are
passionate about. The Company matched these community-driven employee
fundraising efforts to the value of AUD$50,000 with funds going to worthy
organisations such as Food Bank Australia and Giant Steps, among others.

Boehringer Ingelheim Australia was also again proud to partner with leading
community organisations including Guide Dogs Australia and Taronga Conservation
Society, delivering financial and product donations to support the ongoing
health and wellbeing of animals in their care.

“We are incredibly proud to again be named a Top Employer in Australia & New
Zealand. This is especially meaningful after two years of significant
disruption in how we live and work due to the evolving nature of COVID-19. At
Boehringer Ingelheim, our number one priority is of course the safety and
wellbeing of our people. I am very proud of how our teams have not just
adapted, but gone above and beyond to support each other, finding innovative
solutions to ensure an uninterrupted supply of medicines, products and services
to people and animals who rely on them,” said Wes Cook, Regional Managing
Director, Boehringer Ingelheim (Australia & New Zealand).

As a research-driven pharmaceutical company, Boehringer Ingelheim is committed
to create value in areas of unmet medical need and engage with communities and
society to change lives for the better. This has recently been exemplified
through the extension of Boehringer Ingelheim’s initiative Making More Health
(MMH)( called “Boehringer Ingelheim Social
Engagements” with a funding of EUR 50 million.

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the
lives of humans and animals. As a leading research-driven biopharmaceutical
company, the Company creates value through innovation in areas of high unmet
medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim
takes a long-term perspective. Around 52,000 employees serve more than 130
markets in the three business areas, Human Pharma, Animal Health, and
Biopharmaceutical Contract Manufacturing. Learn more at

Source: Boehringer Ingelheim

Source: Boehringer Ingelheim